Sanofi and Regeneron received EU approval for their biologic Dupixent (dupilumab) for adolescents with moderate-to-severe atopic dermatitis, also known as eczema.

The extended marketing authorization now includes adolescents 12 to 17 years of age with moderate-to-severe eczema who are eligible for systemic therapy — making the biologic the first approved in the EU for such patients.

The chronic inflammatory disease is characterized by rashes that can potentially cause intense, constant itching, skin dryness, redness, lesions, crusting and oozing on much of the patient’s body.